3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal

September 16th, 2012 by InvestorPoint

…continued
…continued
   

/C O R R E C T I O N — Jazz Pharmaceuticals/

September 12th, 2012 by InvestorPoint

…continued
…continued
   

Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem

September 10th, 2012 by InvestorPoint

…continued
…continued
   

MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market

September 10th, 2012 by InvestorPoint

…continued
…continued
   

Wolverine Exploration Inc. Announces Fall Drill Program on Cache River Copper/Gold Property in Central Labrador

September 10th, 2012 by InvestorPoint

…continued
…continued
   …continued

3D Systems Makes Fortune’s Fastest-Growing List

September 10th, 2012 by InvestorPoint

…continued
   …continued
…continued
   

Jazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11

September 6th, 2012 by InvestorPoint

…continued
   

Levi & Korsinsky, LLP Announces Investigation of Medicis Pharmaceutical Corporation (MRX), FSI Internaltional Inc. (FSII) and Deltek, Inc. (PROJ)

September 6th, 2012 by InvestorPoint

…continued
   

Merger and Acquisition Activity Within the Biotech Industry Soars to a Four-Year High

September 4th, 2012 by InvestorPoint

…continued
   

Achillion to Raise $41.8 Million Through Registered Direct Offering

August 30th, 2012 by InvestorPoint

…continued
   

Catalyst Pharmaceutical Partners, Inc. Announces Closing of Previously Announced $6 Million Registered Direct Offering

August 30th, 2012 by InvestorPoint

…continued
   

Biotech Industry Merger and Acquisition Activity at a Four-Year High

August 27th, 2012 by InvestorPoint

…continued
   

Icahn Comments On Warning Letter Just Sent By FDA To Forest

August 14th, 2012 by InvestorPoint

…continued
   

DividendStocksOnline.com Releases New Dividend Tracker Toolset

August 14th, 2012 by InvestorPoint

…continued
   …continued
…continued

Icahn Comments on Warning Letter Just Sent by FDA to Forest

August 13th, 2012 by InvestorPoint

…continued
   

New Century Bank Makes Move Into Wake County

August 13th, 2012 by InvestorPoint

…continued
   …continued
   

SABESP Announces 2Q12 Results

August 10th, 2012 by InvestorPoint

…continued
   …continued
   

Icahn Issues Statement: Forest Labs Has Poison Pill Built Into Major License Agreement

August 10th, 2012 by InvestorPoint

…continued
   

NovaBay Pharmaceuticals Provides Second Quarter 2012 Financial Results

August 9th, 2012 by InvestorPoint

…continued
   …continued
…continued
   

Cardiome Reports Second Quarter Results

August 7th, 2012 by InvestorPoint

…continued
   

Momenta Pharmaceuticals Acknowledges Federal Circuit Opinion Supporting Order Issued January 26, 2012 in Ongoing Suit Against Amphastar Pharmaceuticals and Watson Pharmaceuticals

August 3rd, 2012 by InvestorPoint

…continued
   

First Financial Bancorp to Host an Investor Day in Cincinnati, OH on Wednesday, August 15, 2012

August 3rd, 2012 by InvestorPoint

…continued
   …continued
   

Compugen and Merck Serono Ventures to Jointly Establish New Biomarker Company Neviah Genomics Ltd.

June 25th, 2012 by InvestorPoint

GENEVA and TEL AVIV, Israel, June 25, 2012 /PRNewswire/ — Neviah Genomics Ltd. to focus on the discovery and development of novel biomarkers for drug toxicity Compugen to   utilize its predictive   discovery technologies and Merck Serono Ventures to provide the initial funding Neviah Genomics is the first company to be funded within the framework of Merck Serono’s Israel Bioincubator program Merck Serono, a division of Merck, Darmstadt, Germany, and Compugen Ltd. (NASDAQ: CG…continued
     

Watson Announces Completion of New $1.8 Billion Term Loan Facility

June 25th, 2012 by InvestorPoint

PARSIPPANY, N.J., June 25, 2012 /PRNewswire/ – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a new senior secured term loan facility in an aggregate principal amount of $1.8 billion. Borrowings under the new term loan facility bear interest, at a rate equal to LIBOR plus an expected margin of 1.50%, which is subject to a ratings based margin grid. The new five year term loan is fully prepayable. The term loan financing will be used, in conjunction with the i…continued
     

Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR

June 23rd, 2012 by InvestorPoint

PHILADELPHIA, June 23, 2012 /PRNewswire/ — Shire continues to expect to deliver good full year 2012 earnings growth Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that on June 22, 2012, the US Food and Drug Administration (FDA) responded to Shire’s Adderall XR citizen petition.  The FDA’s response requires that all abbreviated new drug applications (ANDAs) have to establish bioequivalence using partial area under the curve measurements at 5 hou…continued
     

« Previous Entries